iPhone 16

IPhone 16 Launch Event: Should You Buy Apple Stock Now

September 9, 2024

The highly awaited event of Apple witnessed the launch of the iPhone 16 series on September 9, 2024. It launches…

Invion

Invion (ASX:IVX): Using Photodynamic Therapy to fight cancer

September 9, 2024

Unless you’re a professional dermatologist, you may not have ever heard of Photodynamic Therapy, let alone thought of it as…

Bio Gene Technology ASX:BTG)

Bio Gene Technology (ASX:BGT): Commercialising a new class of insecticides

September 9, 2024

Bio Gene Technology (ASX:BGT) ASX-listed AgTech company developing two compounds – Flavocide™ and Qcide™ – as insecticides. Investors may hear…

Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals (ASX:PAR): An osteoarthritis solution that could hit the market within 3 years

September 6, 2024

If you thought the were plenty of treatments for osteoarthritis already, Paradigm Biopharmaceuticals (ASX:PAR) is a company that has something…

Cann Group

Cann Group (ASX:CAN): Successfully producing GMP medicinal cannabis since 2017

September 6, 2024

Cann Group (ASX:CAN) is the first company in Australia that was issued a medicinal cannabis license, granted by the Australian…

CET1 ratio

CET1 ratio: If you invest in ASX bank stocks, here’s why it is an important metric to know

September 6, 2024

In this article we look at the Common Equity Tier 1 (CET1) ratio – what it is and why it…

Star Entertainment Group

Star Entertainment Group (ASX:SGR): Where to now in a post-COVID world? Can it avoid a looming cash crunch?

September 5, 2024

In a July interview with the AFR, Star Entertainment Group boss Steve McCann admitted that his company’s pre-pandemic glory days…

Prescient Therapeutics

Prescient Therapeutics (ASX:PTX): About to take the plunge into a Phase 2 trial against T-Cell Lymphoma

September 5, 2024

There’s plenty of ASX oncology biotechs conducting clinical trials, but Prescient Therapeutics (ASX:PTX) is one of the closest to commercialisation.…

annual report of an ASX company

5 crucial things to look for in the annual report of an ASX company that may give you an advantage over other investors

September 5, 2024

5 crucial things to look out for in the annual report of an ASX company! The ASX reporting season is…

Humm Group

Humm Group (ASX:HUM): Its no Big 4 Bank, but has defied the market in 2024

September 4, 2024

Humm Group (ASX:HUM) has not had the year you might expect to a financier that is not either a Big…

ASX stocks at 12 month highs

Here are 5 ASX stocks at 12 month highs, and whether it is time to buy

September 4, 2024

Here are 5 ASX stocks at 12 month highs!   Humm Group (ASX:HUM) Humm has been through a difficult few…

Percheron Therapeutics

Percheron Therapeutics (ASX:PER): Releasing Phase II data by the end of CY24, and successful data could lead to a major re-rate

September 3, 2024

It has been less then a year since Antisense Therapeutics changed its name to Percheron Therapeutics (ASX:PER). It is common…

statutory results

Underlying v Statutory results? There’s a big difference between the 2 – here’s how to tell

September 3, 2024

When companies report results, you’ll hear underlying and statutory results. What is the difference between the two and how big…

Should I buy Woolworths or Coles shares

Should I buy Woolworths or Coles shares in FY25?

September 2, 2024

Should I buy Woolworths or Coles shares? This is one of the top debates Australian investors can have. Obviously, this…

Qantas' capex

Qantas’ capex bill: The company is coping with a $12bn+ bullet for now, but will it eventually bite shareholders?

September 2, 2024

Qantas‘ capex needs are bubbling under the surface, but have not gone away. Former CEO Alan Joyce’s tenure came to…